Proposed change of auditor
Filed with HKEX · Stock code 1541 · · 7 pages · English
Summary by 6ix AI
The change is due to an inability to agree on audit fees related to increased work from a subsidiary's capital increase. A circular with further details will be sent to shareholders in due course.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ImmuneOnco Biopharmaceuticals (Shanghai) Inc on 6ix
Earlier from ImmuneOnco Biopharmaceuticals (Shanghai)
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September, 2026
- Voluntary announcement - completion of capital Increase of a subsidiary
- 2026 Interim Report
- ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
Follow ImmuneOnco Biopharmaceuticals (Shanghai) into a list and get an email when it puts out news.
Follow ImmuneOnco Biopharmaceuticals (Shanghai)